Administration of pamidronate alters bone-titanium attachment in the presence of endotoxin-coated polyethylene particles.
Bisphosphonates are promising in the treatment of periprosthetic osteolysis induced by particulate wear debris. The in vivo effects of pamidronate with different doses and durations of administration on bone-titanium attachment in the presence of endotoxin-coated polyethylene particles were examined in a rat model in this study. Titanium pins and endotoxin-coated polyethylene particles were introduced into rat femoral canals followed by intraperitoneal injection of pamidronate every other day. The treatment varied in the dose from 0 to 40 microg/kg and the duration of either 10 days or 6 weeks. Bilateral femurs were harvested after 6 weeks and examined by bone densitometer and MicroCT scan. Pamidronate increased the bone density of the left, unoperated femurs in a dose and duration dependent manner. Bone-titanium attachment significantly increased in all treatment groups compared to the control group. When pamidronate was administered for 10 days, the increase of bone-titanium attachment was significantly dose-dependent. However, when pamidronate was given for 6 weeks at 4 microg/kg, the bone-titanium attachment was significantly (p < 0.001) lower compared to the 10 day treatment of the same dose, although it was significantly higher than controls. Our results suggest that pamidronate effectively increase bone-titanium attachment even in the presence of endotoxin-coated polyethylene particles. However, long-term administration may reduce its efficacy.
Xing
Zhiqing
Z
Department of Orthopaedic Surgery, University of Tennessee--Campbell Clinic, Memphis, Tennessee 38163, USA. zhiqingx@orthosurg.ucsf.edu
Hasty
Karen A
KA
Smith
Richard A
RA
D015502:Absorptiometry, Photon; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001842:Bone and Bones / Q000737:chemistry / Q000000981:diagnostic imaging / Q000187:drug effects; D004164:Diphosphonates / Q000008:administration & dosage*; D004731:Endotoxins / Q000009:adverse effects; D005260:Female; D005269:Femur / Q000737:chemistry / Q000000981:diagnostic imaging / Q000187:drug effects*; D006622:Hip Prosthesis / Q000009:adverse effects*; D007274:Injections, Intraperitoneal; D010014:Osteolysis / Q000139:chemically induced / Q000188:drug therapy*; D000077268:Pamidronate; D020959:Polyethylene / Q000009:adverse effects* / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D014025:Titanium / Q000009:adverse effects* / Q000737:chemistry
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004731:Endotoxins; D020959:Polyethylene; D014025:Titanium; D000077268:Pamidronate